Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Background Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects. In SCID/NOD mice, defibrotide showed activity in human myeloma xenografts. This phase I/II study was conducted to identify the most appropriate dose of defibrotide in co...

Full description

Bibliographic Details
Main Authors: Antonio Palumbo, Alessandra Larocca, Mariella Genuardi, Katarzyna Kotwica, Francesca Gay, Davide Rossi, Giulia Benevolo, Valeria Magarotto, Federica Cavallo, Sara Bringhen, Cecilia Rus, Luciano Masini, Massimo Iacobelli, Gianluca Gaidano, Constantine Mitsiades, Kenneth Anderson, Mario Boccadoro, Paul Richardson
Format: Article
Language:English
Published: Ferrata Storti Foundation 2010-07-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/5657

Internet

https://haematologica.org/article/view/5657

Similar Items